Quality and duration of survival in glioblastoma multiforme. Combined surgical, radiation, and lomustine therapy.
A retrospective evaluation of the quality and length of survival of 74 patients nonrandomly receiving lomustine, 100 to 110 mg/sq m, following craniotomy and irradiation for glioblastoma multiforme was performed. After surgery all patients were capable of at least partial self-care. Patients receiving postoperative irradiation and lomustine had a median survival of 11.5 months. While receiving chemotherapy, 40% of these patients were capable of at least partial employment; 75% were able to care for themselves. These levels of function were stable for 70% of the average postoperative course (8.0 months), following which a decline ensued.
D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D004361:Drug Tolerance; D005909:Glioblastoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011182:Postoperative Care; D011379:Prognosis; D011788:Quality of Life; D013997:Time Factors
D009607:Nitrosourea Compounds; D008130:Lomustine